OTCMKTS:HPPI

HedgePath Pharmaceuticals Stock Forecast, Price & News

$0.08
0.00 (0.00 %)
(As of 04/15/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.06
Now: $0.08▼
$0.08
50-Day Range
$0.06
MA: $0.09▼
$0.12
52-Week Range
$0.04
Now: $0.08▼
$0.32
Volume15,808 shs
Average Volume19,283 shs
Market Capitalization$27.78 million
P/E RatioN/A
Dividend YieldN/A
Beta-1.16
HedgePath Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for patients with cancers and non-cancerous proliferation disorders in the United States. It primarily focuses on the development of therapies for skin, lung, and prostate cancers. The company's Hedgehog signaling pathway is a primary regulator of cellular processes in vertebrates, including stem cell maintenance, cell differentiation, tissue polarity, and cell proliferation. It also develops super bioavailability (SUBA)-itraconazole oral capsules for patients with basal cell carcinoma nevus syndrome. SUBA-Itraconazole is a patented itraconazole formulation that enhances the absorption of itraconazole to enhance the bioavailability of orally administered drugs that are poorly soluble. The company was founded in 1992 and is headquartered in Tampa, Florida. HedgePath Pharmaceuticals, Inc. is a subsidiary of Mayne Pharma Ventures Pty Ltd.

Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:HPPI
Previous Symbol
CUSIPN/A
CIK1042418
Webwww.hedgepathpharma.com
Phone813-509-2417
Employees2
Year FoundedN/A

Debt

Debt-to-Equity RatioN/A
Current Ratio6.76
Quick Ratio6.76

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value($0.01) per share
Price / Book-7.50

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-4,550,000.00
Net MarginsN/A
Return on EquityN/A
Return on Assets-246.03%

Miscellaneous

Outstanding Shares370,446,000
Market Cap$27.78 million
Next Earnings DateN/A
OptionableNot Optionable

Headlines

HedgePath Pharmaceuticals Announces Name Change to INHIBITOR Therapeutics, Inc. and Ticker Symbol Change to "INTI" Effective August 20, 2019
August 19, 2019 |  finance.yahoo.com
HedgePath Pharmaceuticals Announces Notice of Allowance with Additional Claims Governing the Use of SUBA®-Itraconazole for the Treatment of Lung Cancer
May 29, 2019 |  finance.yahoo.com
HedgePath Pharmaceuticals Announces Notice of Allowability of U.S. Patent Application Regarding Treatment of Prostate Cancer
May 6, 2019 |  finance.yahoo.com
W. Mark Watson Elected as Chairman of the Board of HedgePath Pharmaceuticals
April 15, 2019 |  finance.yahoo.com
HedgePath Pharmaceuticals Provides Corporate Update for the Fourth Quarter and Year End 2018
March 7, 2019 |  finance.yahoo.com
See More Headlines

MarketRank™

Overall MarketRank™

0.44 out of 5 stars

Medical Sector

1701st out of 2,025 stocks

Commercial Physical Research Industry

36th out of 42 stocks

Analyst Opinion: 0.0Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
$0.08
0.00 (0.00 %)
(As of 04/15/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive HPPI News and Ratings via Email

Sign-up to receive the latest news and ratings for HPPI and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











HedgePath Pharmaceuticals (OTCMKTS:HPPI) Frequently Asked Questions

What stocks does MarketBeat like better than HedgePath Pharmaceuticals?

Wall Street analysts have given HedgePath Pharmaceuticals a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but HedgePath Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How has HedgePath Pharmaceuticals' stock been impacted by Coronavirus (COVID-19)?

HedgePath Pharmaceuticals' stock was trading at $0.0799 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, HPPI stock has decreased by 6.1% and is now trading at $0.0750.
View which stocks have been most impacted by COVID-19.

Who are HedgePath Pharmaceuticals' key executives?

HedgePath Pharmaceuticals' management team includes the following people:
  • Mr. Nicholas Jon Virca, Pres & CEO (Age 73)
  • Mr. Garrison J. Hasara CPA, CPA, CFO, Treasurer, Sec. & Chief Compliance Officer (Age 50)

Who are some of HedgePath Pharmaceuticals' key competitors?

Some companies that are related to HedgePath Pharmaceuticals include Eloxx Pharmaceuticals (ELOX), Cleveland BioLabs (CBLI), Bioqual (BIOQ), ProMIS Neurosciences (ARFXF), NanoViricides (NNVC), AIkido Pharma (AIKI), Inhibitor Therapeutics (INTI), Tenax Therapeutics (TENX), U.S. Stem Cell (USRM), Vitality Biopharma (VBIO), DNAPrint Genomics (DNAG), Protalex (PRTX), Affinity Energy and Health (ALGXY), Deltagen (DGEN) and Redpoint Bio (RPBC).
View all of HPPI's competitors.

What other stocks do shareholders of HedgePath Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other HedgePath Pharmaceuticals investors own include TransAtlantic Petroleum (TAT), Eaton (ETN), Diamond Offshore Drilling (DO), Correvio Pharma (CORV), The Clorox (CLX), CIT Group (CIT), Bank of Montreal (BMO), Blue Sphere (BLSP), BJ's Wholesale Club (BJ) and Alimentation Couche-Tard (ATD.B).

What is HedgePath Pharmaceuticals' stock symbol?

HedgePath Pharmaceuticals trades on the OTCMKTS under the ticker symbol "HPPI."

How do I buy shares of HedgePath Pharmaceuticals?

Shares of HPPI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is HedgePath Pharmaceuticals' stock price today?

One share of HPPI stock can currently be purchased for approximately $0.08.

How much money does HedgePath Pharmaceuticals make?

HedgePath Pharmaceuticals has a market capitalization of $27.78 million.

How many employees does HedgePath Pharmaceuticals have?

HedgePath Pharmaceuticals employs 2 workers across the globe.

What is HedgePath Pharmaceuticals' official website?

The official website for HedgePath Pharmaceuticals is www.hedgepathpharma.com.

Where are HedgePath Pharmaceuticals' headquarters?

HedgePath Pharmaceuticals is headquartered at 4830 W. Kennedy Blvd. Suite 600, Tampa FL, 33609.

How can I contact HedgePath Pharmaceuticals?

HedgePath Pharmaceuticals' mailing address is 4830 W. Kennedy Blvd. Suite 600, Tampa FL, 33609. The company can be reached via phone at 813-509-2417 or via email at [email protected]


This page was last updated on 4/17/2021 by MarketBeat.com Staff

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.